CareFusion to pay $40 million to settle U.S. kickbacks lawsuit

Thu Jan 9, 2014 3:07pm EST

(Reuters) - CareFusion Corp agreed to pay $40.1 million to settle a federal government lawsuit accusing it of paying kickbacks to boost sales of a pre-surgical skin treatment, and marketing the product for unapproved uses.

The accord announced on Thursday by the U.S. Department of Justice resolves allegations that CareFusion violated the federal False Claims Act by paying $11.6 million to a doctor to promote its ChloraPrep product to healthcare providers.

That doctor, Charles Denham, received the kickbacks while serving as co-chair of the safe practices committee of the nonprofit National Quality Forum, which makes recommendations on healthcare practices, the Justice Department said.

"Corrupting the standard-setting process through kickbacks can affect the healthcare treatment choices that doctors and hospitals may make for patients," Stuart Delery, assistant attorney general for the Justice Department's civil division, said in a statement.

The lawsuit also claimed that CareFusion promoted ChloraPrep from September 2009 through August 2011 for unapproved uses.

The U.S. Food and Drug Administration had approved ChloraPrep to prepare patients' skin for surgery or injections.

CareFusion said on Thursday that it set aside funds for the settlement in the first quarter of 2013.

Chief Executive Officer Kieran Gallahue said the San Diego-based company is pleased to settle, and has made "significant investments" to improve its quality and compliance practices, including in sales and marketing.

Denham could not immediately be reached for comment.

The accord resolved a whistleblower lawsuit first brought in September 2010 by Cynthia Kirk, a former vice president of regulatory affairs at a CareFusion infection prevention unit.

She will receive $3.26 million through the settlement, which along with the lawsuit was unsealed this week by the federal court in Kansas City, Kansas.

In afternoon trading, CareFusion shares were up 81 cents at $41.12.

The case is U.S. ex rel. Kirk v. CareFusion Corp et al, U.S. District Court, District of Kansas, No. 10-02492.

(Editing by Jan Paschal)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
Lewayne wrote:
It’s a sad day in the United States when our government fines a company for marketing a skin prep for surgical procedures that require skin antisepsis, and is backed by numerous studies showing its safety and effectiveness, including a multi-center, randomized, controlled trial that was published in the New England Journal of Medicine, yet so called “health” companies like Arbonne, get to promote their products that have never been studied. Let’s add to the irony, another government agency, the CDC, promotes this same product for the help in preventing catheter-related bloodstream infections with a Category IA. Recommendation-“ Strongly recommended for implementation and strongly supported by well-designed experimental, clinical, or epidemiologic studies” , and the other agency gets to fine the company for promoting its product to be used before the placement of a central line.

Jan 15, 2014 9:49am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

A tourist takes a plunge as she swims at Ngapali Beach, a popular tourist site, in the Thandwe township of the Rakhine state, October 6, 2013. Picture taken October 6, 2013. REUTERS/Soe Zeya Tun (MYANMAR - Tags: SOCIETY) - RTR3FOI0

Where do you want to go?

We look at when to take trips, budget considerations and the popularity of multigenerational family travel.   Video